Patents by Inventor Michel Monsigny

Michel Monsigny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6372499
    Abstract: The complex has at least one negatively charged nucleic acid bonded to at least one positively charged polymeric conjugate The conjugate containing a polylysine formed from monomers having free NH3+ groups, and having at least 10% of the free NH3+ groups substituted by residues which can be protonated in a weakly acid medium causing destabilization of cell membranes. Optionally, some of the free NH3+ groups can be substituted by a molecule with a recognition signal by a cell membrane receptor. The free NH3+ groups of the said polylysine make up at least 30% of the monomers of the polymeric conjugate. The residue that causes the destabilization of cell membrane in weak acid of quinolines of the formula: where R1 is hydrogen, R2 is —(CH2)n13 CO2—H, X is hydrogen or chlorine and n is an integer from 1 to 10. The signal is a simple oside or a disaccharide or peptide.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: April 16, 2002
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Patrick Midoux, Michel Monsigny
  • Patent number: 6251858
    Abstract: The invention relates to compounds comprising one or several oligosides, each of said oligosides being fixed in a covalent manner on one or many molecules, matrixs or particles, specifically one, two or three, via an intermediary molecule possessing a nitrogen atom carried by a carbon in &agr; of a C═O group and one or many functional groups, specifically one, two or three, the covalent bond between said intermediary molecule and the oligoside being done by the intermediary of said nitrogen atom, and the covalent bond between said intermediary molecule and said molecule, said matrix, said particle, or said molecules, said matrixs, said particles being done by the intermediary of the said functional groups of said intermediary molecule and appropriate functional groups to the molecule(s), the matrix(ces) or the particle(s).
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: June 26, 2001
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Michel Monsigny, Annie-Claude Roche, Nadia Sdiqui, Roger Mayer
  • Patent number: 5733762
    Abstract: A compound consisting essentially of polylysine conjugated to non-charged residues and recognition signals wherein the free amino functions of said polylysine are substituted with non-charged residues and said recognition signals, which non-charged residues consist of gluconalactone and which recognition signals are at least one member of the group consisting of galactoside, mannoside, fucoside, Lewis.sup.x, Lewis.sup.b, oligomannoside, oligolactosamine saccharides and peptide ANP and said conjugated polylysine contains at least 30% unsubstituted free amino functions and a method of transfecting cultured cells.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: March 31, 1998
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Patrick Midoux, Patrick Erbacher, Annie-Claude Roche-Degremont, Michel Monsigny
  • Patent number: 5686103
    Abstract: The invention concerns a method of binding a product to the membrane of a melanocyte by means of a ligand-receptor bond, which comprises using a product consisting of a basic structure coupled to at least one ligand consisting of an oside residue accessible to the membrane receptors, said oside residue being a fucose residue, notably an Alpha-L-fucose residue.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: November 11, 1997
    Assignee: Parfums Christian Dior
    Inventors: Gerard Redziniak, Dominique Cerdan, Claudine Kieda, Michel Monsigny
  • Patent number: 5595897
    Abstract: The invention concerns a complex between at least one negatively charged nucleic acid and at least one positively charged polymeric conjugate, the link between the nucleic acid and the polymeric conjugate being electrostatic in nature, the polymeric conjugate containing a polymer formed from monomer components having free NH.sub.3.sup.+ functions of the aforementioned components and being as follows:--the free NH.sub.3.sup.+ functions from the aforementioned components are substituted in a ratio of at least 10%, advantageously from 45% to 70%, particularly 60%, by noncharged residues leading to a reduction of positive charges in comparison to the same nonsubstituted polymeric conjugate, facilitating the release of nucleic acid by the dissociation of the complex,--the aforementioned residues possess in addition the following properties:.fwdarw.they contain at least one hydroxyl group,.fwdarw.they do not correspond to a recognition signal recognized by a cellular membrane receptor,--the free NH.sub.3.sup.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: January 21, 1997
    Assignee: I.D.M. Immuno-Designed Molecules
    Inventors: Patrick Midoux, Patrick Erbacher, Annie-Claude Roche-Degremont, Michel Monsigny
  • Patent number: 5332575
    Abstract: The invention concerns a method of binding a product to the membrane of a melanocyte by means of a ligand-receptor bond, which comprises using a product consisting of a basic structure coupled to at least one ligand consisting of an oside residue accessible to the membrane receptors, said oside residue being a fucose residue, notably an Alpha-L-fucose residue.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: July 26, 1994
    Assignee: Parfums Christian Dior
    Inventors: Gerard Redziniak, Dominique Cerdan, Claudine Kieda, Michel Monsigny
  • Patent number: 5286629
    Abstract: The invention relates to products which are to be bound specifically to the membrane of a keratinocyte by means of a ligand-receptor bond.These products carry at least one ligand consisting of an oside residue selected from .alpha.-L-rhamnose, .alpha.-D-galactose and .alpha.-D-galactose-6-phosphate.By virtue of this specificity, it is possible to prepare cosmetic or pharmaceutical compositions having an improved efficacy in particular, for example for regeneration of the epidermis, for the treatment of psoriasis or for renewed hair growth.
    Type: Grant
    Filed: November 4, 1991
    Date of Patent: February 15, 1994
    Assignee: Parfums Christian Dior
    Inventors: Alain Denis, Claudine Kieda, Michel Monsigny, Pierre Perrier, Gerard Redziniak
  • Patent number: 4801578
    Abstract: Macromolecular conjugates of muramylpeptides useful as a stimulant of the cellular immune systems have the formula (R--X).sub.m --(LAM) wherein R is an N-acetylmuramylpeptidyl group or a derivative thereof; (LAM) is a neoglycoprotein having affinity for macrophages or monocytes, consisting of a protein covalently substituted by more than five glycidic chains, each having at least five osidic units, X is a covalent bond between a functional group of the peptidic part of R and a functional group of (LAM) or X is the residue of a conventional bifunctional coupling agent capable of bonding to R and (LAM) by formation of covalent bonds; and m is a number greater than or equal to 1.
    Type: Grant
    Filed: June 4, 1984
    Date of Patent: January 31, 1989
    Assignee: Establishment Public dit Centre National de la Recherche Scientifique (CNRS)
    Inventors: Michel Monsigny, Annie-Claude Roche
  • Patent number: 4753984
    Abstract: A prodrug comprises a polyhydroxylated polyamine to which a drug is linked by the intermediary of a peptidyl group. The prodrug is useful as an antitumor or antiparasite medicine.
    Type: Grant
    Filed: June 9, 1986
    Date of Patent: June 28, 1988
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Francis Delmotte, Michel Monsigny, Pierre-Jean Lescanne, Francois Daussin
  • Patent number: 4703107
    Abstract: Peptide derivatives of aminodrugs have longer lasting effects than the drugs without the peptide radical.
    Type: Grant
    Filed: December 3, 1985
    Date of Patent: October 27, 1987
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Michel Monsigny, Roger Mayer
  • Patent number: 4576745
    Abstract: Method for determining endotoxins in a liquid, wherein said liquid is contacted, at 20.degree.-40.degree. C., with a lysate of limule amebocytes and an aqueous solution of a peptide having the following formula: ##STR1## in which [Pept-- is a peptidic hydrophobic chain, n is 1, 2, 3, 4, or 5, B is ##STR2## being H or CH.sub.3, --NH--Ar] is the residue of a fluorescent heteroaromatic amine and X.sup..crclbar. is an anion, the pH of the thus obtained medium is adjusted at 5 to 10 and the heteroaromatic amine thus formed is determined by fluorimetry, and new peptides according to formula (I) usable in said method.
    Type: Grant
    Filed: September 9, 1982
    Date of Patent: March 18, 1986
    Assignee: Centre National de la Recherche Scientifique
    Inventor: Michel Monsigny